laquinimod 0.6

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Relapsing Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Phase 2

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

CompletedNCT00349193

Teva Branded Pharmaceutical Products R&D, Inc.Relapsing Remitting Multiple Sclerosis

Start: 2005-03-31End: 2006-08-31Updated: 2011-04-08

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

WithdrawnNCT01404117

Teva Branded Pharmaceutical Products R&D, Inc.Relapsing Multiple Sclerosis

Start: 2012-03-31End: 2014-01-31Updated: 2013-08-27

Related Papers

Laquinimod therapy in multiple sclerosis: a comprehensive review.

2014-05-0610 citations

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

2008-06-01185 citations